BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

Core Insights - BXCL501 has shown clinical benefits and a favorable tolerability profile for treating opioid withdrawal symptoms, supporting its potential future development in this area [1][2][3] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience [10] - The company is focused on re-innovating existing approved drugs and leveraging big data and machine learning to identify new therapeutic indications [10] Study Findings - The Phase 2 trial indicated that BXCL501 may be as effective as or superior to lofexidine for reducing opioid withdrawal symptoms during methadone taper, with a more convenient dosing regimen [3][4] - BXCL501 demonstrated lower rates of cardiovascular effects compared to lofexidine, particularly in orthostatic hypotension (18% for BXCL501 vs 50% for lofexidine, p<0.05) [3] - Patients receiving BXCL501 240 µg experienced over a 30% reduction in withdrawal symptoms as measured by the Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) [8] Market Context - Opioid use disorder (OUD) is a significant global health crisis, affecting approximately 5.9 million adults in the U.S. and an estimated 36 to 61 million people worldwide [9] - Despite the high prevalence of OUD, only about 25% of individuals with substance use disorders receive specialized treatment, indicating a substantial treatment gap [9] Product Profile - BXCL501 is an investigational orally dissolving film formulation of dexmedetomidine, designed for the acute treatment of agitation associated with various conditions, including opioid withdrawal [11] - The product has been granted Breakthrough Therapy designation by the FDA for certain indications, highlighting its potential as a safe and effective treatment option [11]